Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma.
Phase 1
- Conditions
- Relapsed and/orRefractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-504367-16-00
- Lead Sponsor
- Celgene International II S.a.r.l.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
Age = 18 with history of RRMM treated with = 3 prior lines of antimyeloma therapy (Part A) or 1 to 3 prior lines of anti-myeloma therapy (Parts B and C)., Measurable MM by central laboratory., Eastern Cooperative Oncology Group performance status of 0 to 1., Adherence to contraception requirements.
Exclusion Criteria
Prior treatment with mezigdomide or alnuctamab., Other exclusion criteria can be found in the protocol.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method